drugset / Trial / NCT05220878

Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP

NCT05220878

Phase 3 Completed 160 enrolled AO GENERIUM
RandomizedParallel-groupDouble-blindTreatment

Summary

It is a phase III multicenter randomized double-blinded comparative study of clinical efficacy and safety of GNR-069 and Nplate in patients with idiopathic thrombocytopenic purpura

Timeline

Start
2021-09-09
Primary completion
2023-08-22
Completion
2023-10-19

Drugs

EvaluationDrugModalityDoseRoute
Subject GNR-069 Protein / enzyme biologic 1 ug/kg Subcutaneous
Comparator Romiplostim Peptide 1 ug/kg Subcutaneous